Introduction
Selenium (Se) and its metabolites occur in organisms from a range of phyla including microorganisms, fungi, plants, animals and humans and is incorporated into Se-proteins such as the antioxidant enzymes glutathione peroxidases or selenoprotein-P (SelP), a transport protein for Se. Current reports on the metabolism of Se have proposed that the metabolic cycle and excretion from humans include both inorganic and organic molecular species of Se present at various oxidation states including À2, +2, +4 and +6. 1 The formation of elemental Se (oxidation state 0, Se 0 ) has less often been studied as part of metabolic processes. 2 Nevertheless, Se 0 has been reported to occur in soils where microbes drive the redox cycle between on one hand the oxidized species selenate (Se(VI)) and selenite (Se(IV)) and on the other hand the reduced Se 0 . 3 Furthermore, Se(IV) can be reduced to nanometer-sized particles of Se 0 by fungi, which expelled the nanostructures through their cell membrane as a protective mechanism. 4 Following enrichment of a culture of Lactobacillus bulgaricus with Se(IV), amorphous Se 0 nanoparticles (Se 0 NPs) were formed outside and inside their cytosol, and this Se 0 -enriched culture was suggested as a safe dietary source of Se. 5 Transmission electron microscopy (TEM) with element-selective energy-dispersive X-ray fluorescence (EDX) proved to be a convenient tool in these studies for imaging of the Se 0 NPs and to provide evidence of their identity. The absorption rate of Se 0 obtained from bacteria was tested and showed a modest availability in chickens at 2% of that of Se(IV). 6 Synthetically made Se 0
NPs have been selectively engineered as novel Se supplements by derivatizing their surface with bioinspired materials such as a polysaccharide to improve the stability of the NPs, 7 or by using a catechin-derivative 8 to allow pH-dependent stability against aggregation in liquid suspension prior to biological experimentation. In the search for a bioavailable and bioactive, yet non-toxic form of Se, red Se 0 NPs, which were synthesized in the presence of and stabilized by bovine serum albumin (BSA), were orally administered to rats. The results showed a high degree of bio-activity comparable with that of Se(IV) as Se-dependent enzymes were up-regulated, yet the acute and short-term toxicities were lower than that of Se(IV). 9, 10 In order to further investigate its potential as a chemopreventive agent, the toxicity of Se 0
NPs was compared with that of selenomethionine (SeMet) 11 or methylselenocysteine (MeSeCys) in a short-term study with mice. 12 The results showed less toxicity of the nanoform, and Se 0 NPs were as efficient as the two molecular Se forms in inducing the formation of Se-dependent enzymes. In a sub-chronic toxicity study with rats, the nano-Se source was inferior in toxicity to that of Se(IV) or Se-rich protein used as sources of Se. 13 Combined these results demonstrated a beneficial, lower acute and sub-chronic toxicity of Se 0 . When used as a feed additive Se 0 NPs improved the intrinsic immunedefense system of sheep, rumen fermentation as well as utilization of the animals' feed. 14, 15 Regarding the Se retention in blood and tissues of experimental animals, no significant difference in the selenium concentration in blood, liver and kidneys was observed after 7 days of repeated administration of Se 0 NPs or MeSeCys to mice at nutritional levels (0.035 and 0.070 mg kg À1 bw per day). However, when administering a supra-nutritional dose (1 mg kg À1 bw per day) the Se concentration was higher in the MeSeCys exposed animals. 12 NPs was calculated from the difference in Se concentration in the sample (no sulfite treatment) and that in the supernatant of the sulfite-treated sample. 12 The indirect nature of this analytical approach would benefit from a more direct method of analysis for the SeSO 3 2À reaction product.
The aim of the present study was to investigate the absorption, distribution, metabolism and excretion (ADME) of Se 0 NPs stabilized with BSA in rats that were repeatedly exposed via oral gavage for 28 days. Two doses of Se, one close to physiological dose at 0.05 mg Se per kg bw per day or one supra-nutritional dose at 0.5 mg Se per kg bw per day, were administered daily. For comparison Se(IV) was used as positive control. In order to most accurately describe the ADME of Se, its concentrations were determined in selected tissues, feces and urine using state-of-the-art mass spectrometric methods of analysis for Se and Se species analysis. Dynamic light scattering (DLS) or TEM were used for characterization of the particle size in the Se 0 NP suspension prior to dosage.
Experimental

Selenium nanoparticles and chemicals
A suspension of red amorphous Se NPs was synthesized by reduction of sodium selenite with glutathione in the presence of BSA as described in detail elsewhere. 9 A solution of 0.2 M sodium sulfite (BRR, Prolabo, Leuven, Belgium) was prepared in ultra-pure water, which was obtained from a Millipore Element apparatus (Millipore, Milford, MA, USA). The pH of the freshly prepared solution was 9.5. The solvents used for the high performance liquid chromatography (HPLC) analyses were freshly He-degassed ultrapure water and methanol (Rathburn Chemicals Ltd., Walkerburn, Scotland). Solutions of selenocystine (SeCys 2 ) (Sigma-Aldrich, Copenhagen, Denmark) and of selenodiglutathione (GSSeSG) (PharmaSe, Lubbock, TX, USA) were prepared in He-degassed ultra-pure water. Aqueous solutions of selenite (Se(IV)), selenate (Se(VI)) and selenomethionine (SeMet) were prepared as described previously.
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Characterization of the Se 0 nanoparticle suspension
The concentration of Se in the suspension of Se 0 NPs was determined following digestion by nitric acid (see the following section on Se analysis) by inductively coupled plasma mass spectrometry (ICP-MS) (7500ce, Agilent Technologies, Japan) run in the collision-reaction cell (CRC) mode with He as interferencereducing cell gas. The content of non-particulate Se in the suspension was determined following filtration through a 12 kDa molecular weight cut-off cartridge (VectaSpin Micro Centrifuge Filter, Whatman, England) at 13 400 rpm (12 100 Â g) for 10 minutes in a microcentrifuge (Eppendorf MiniSpin, Eppendorf AG, Hamburg, Germany). After digestion the acidic samples were diluted with a mixture of ultra-pure water and 3% methanol 18 to approximately 2% nitric acid concentration. The concentration of Se was quantified using external calibration with yttrium (Y) as the internal standard (SCP Science, Quebec, Canada). The limit of detection (3s) was 17 and 2 mg Se per mL for the suspensions and filtrates, respectively. The size distribution of each produced batch was determined by DLS and laser Doppler velocimetry was used for characterization of zeta-potential of the nanoparticles in suspension using a Zetasizer Nano-ZS (Malvern Instruments, UK). the cuvette were determined automatically by the instrument. For the calculation of the nanoparticle size distribution the viscosity of water was used. The optical parameters for selenium's index of refraction n = 3.37 and index of absorption k = 0.52 at 633 nm were applied. 19 The size and shape of the Se 0 NPs were imaged by TEM using a TEM Philips CM100 instrument (FEI, Eindhoven, The Netherlands) at 80 kV accelerating voltage. Prior to recording, the Se 0 NP suspension was diluted 10 times with deionized water. A drop of the suspension was applied to a formvar-coated copper grid.
Instrumentation
For the chromatographic separation of Se species, the HPLC flow was delivered using a quaternary, metal-free HPLC pump and an autosampler. Details of the anion exchange chromatographic system used for SeSO 3 2À separations, the heparin-affinity HPLC system used for SelP analysis and the reversed-phase or cation exchange HPLC systems used for urine metabolites 20, 21 are given in ESI, † Se was monitored using an ELAN 6000 ICP-MS instrument. Instrumental details for ICP-DRC-MS and for HPLC instrumentation were as described previously.
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Animal study
Four week old female Wistar Hannover Galas rats with a specific pathogen-free health status were purchased from M&B Taconic (Lille Skensved, Denmark). Upon arrival the rats were allowed to acclimatize for a week before the start of the experiment. The body weight of the animals at the beginning of the study was (mean AE one s.d.) 132 AE 15 g (N = 44). The rats were housed conventionally with two animals per cage (Macrolon, Techniplats Gazzada S. ar. L., Buguggiate, Italy) with a 12 : 12 h reversed light-dark cycle from 7 p.m. to 7 a.m. The room temperature was 22 AE 1 1C and the relative humidity was 55% AE 5%. The rats were given ad libitum a standard diet (Altromin rat No.1324, Brogården, Gentofte, Denmark) and citric acid acidified (pH 3) tap water to avoid microbiological contamination of drinking water. The composition of the standard feed provided the animals with all necessary nutrients including an intake of vitamin E of 5.7 mg kg À1 bw per day. The animal study was performed under conditions approved by the Danish Animal Experiments Inspectorate and the in-house Animal Welfare Committee. The rats were randomized into six groups, two of which during 28 consecutive days once daily orally by gavage received 100 mL kg solutions of the Se(IV) sodium salt were dosed at the same two doses (N = 8 per group). On day 15 of the study the rats were placed individually for 24 hours in metabolism cages for collection of urine and feces on dry ice. During this time the animals had access to water, but not to feed. On day 28 the rats were fasted overnight before euthanization on day 29 where they were anaesthetized in CO 2 /O 2 and decapitated. Blood from the neck wound was collected on heparin and plasma was prepared by centrifugation (1000 Â g at 0 to 4 1C for 10 min) and organs were removed. From six animals from each of the groups exposed to 0.5 mg kg À1 bw per day of Se 0 NPs or Se(IV), the stomach (corpus ventriculi), muscle (right biceps femoris) and brain, which were transferred to ice-cold 0.32 M sucrose and homogenized by focused ultrasound, were reserved for chemical analysis. From the same animals, the liver (lowest part of the left median lobe), left kidney and feces were sampled for total Se and Se 0 analysis, whereas blood plasma was subjected to total Se and SelP analysis.
Sample preparation and analysis of Se, SelP and elemental Se
Sub-samples of animal organs were mixed with nine times excess of ultra-pure water in a 50 mL polyethylene tube and homogenized using an Ultra Turrax homogenizer (DI 25 Basic, Ika-Werke, Staufen, Germany). The homogenates were frozen and stored at À18 1C until time of analysis. The complete feces were collected and dried at 80 1C for 4 days. The dry samples were homogenized using a mortar and pestle and stored in a desiccator until time of analysis. The content of Se in the biological samples, in the Se 0 NP-suspension and in the filtrates were determined by ICP-DRC-MS following microwave-assisted wet-ashing by nitric acid of 300 mg of tissue, 100 mg of feces or 1 mL of urine using a methodology described previously. 17 The thawed blood plasma samples were passed through a 0.45 mm filter (Whatman Mini-UniPrep, Clifton, NJ, USA) and subjected to separation of the SelP by heparin affinity HPLC (Table S1 , ESI †). Quantification was carried out using post-column isotope dilution using an enriched (99.2%) 77 Se standard. 24 The enriched isotope (10 ng Se per mL using mobile phase A as solvent) was pumped using a peristaltic pump and its accurate flow was monitored daily by weighing. The enriched stable isotope and the eluent from the HPLC column were mixed via a T-piece before entry into the nebulizer of the ICP-DRC-MS, which was used to detect the spike isotope ( Diagnostics, Oslo, Norway) with a reference value for Se of 58.6 ng Se per mL was used. For the in situ synthesis of the ion in tissues and feces, 500 mL of the organ homogenate or 50 mg of the dry feces containing Se 0 were mixed with 250 mL of the 0.2 M sulfite solution and water to a final volume of 1500 mL. The mixture was placed in a flat bottom glass vial in a water bath at 50 1C for 20 minutes using magnetic stirring. After cooling, the mixture was purified by passage through a disposable C 18 filter cartridge mounted in series with a membrane filter with a 0.45 mm pore size. Prior to HPLC analysis, sub-samples of one for every ten of the sulfite-treated control samples were spiked with 0, 100 or 200 ng Se per mL as Se(VI), which was co-chromatographed and used to construct a standard additions calibration curve for Se on the basis of chromatographic peak area. Anion exchange HPLC ( by DLS is shown in Fig. 1 . The major fraction of the nanoparticles had a diameter in the range of 10 to 80 nm with a maximum of the size distribution (mean AE one s.d.) at 19 AE 1 nm. A small fraction of the Se 0 NPs was present as micrometer sized aggregates, which could not be dispersed by ultrasound. The size distribution was determined immediately before and after the animal study to ensure that nanoparticles with the same size characteristics were administered to the rats throughout the animal study. Transmission electron microscopy ( Fig. 1) confirmed the determined diameter and showed that the particles had a spherical shape. The total selenium concentration in the suspensions was (mean AE one s.d.) 380 AE 3 mg mL À1 . The amount of unbound selenium was undetectable (o2 mg mL
Results and discussion
À1
) showing that all administered Se was in the form of nanoparticles.
Absorption and distribution of Se
The animal study included two Se dose levels for each chemical form, i.e. Se 0 NPs and Se(IV). The low dose at 0.05 mg Se per kg bw per day was chosen as toxicological effects were not expected, and the high dose at 0.5 mg Se per kg bw per day was chosen as a supra-nutritional dose where toxicological effects were likely to occur. 12, 13 The intrinsic Se concentration in the rats' feed was (mean AE one s.d.) 250 AE 54 ng g À1 (N = 3), which influenced the Se content in the control animals. Considering an average consumption of feed for a rat of around 15 g per day, the control animals received about 0.03 mg Se per kg bw per day via the feed. The distribution of Se in a range of organs, blood plasma, urine and feces from rats, that were administered the highest dose, and in corresponding controls, was analyzed by ICP-DRC-MS (Fig. 2) . The largest concentrations were detected in the metabolically active organs liver and kidneys. The Se contents in most biological samples were not different for the two dosage forms. In lungs however, the Se content was higher following dosage with Se(IV), but the reason for this slightly higher content remains unknown. The results in Fig. 2 demonstrated that the bioavailability in rats of Se 0 NPs was similar to that observed for Se(IV) as indicated by the plasma concentrations. For the animals, which received 0.5 mg Se per kg bw per day the recovery of Se in their feces amounted to (mean AE one s.d.) 12 AE 5% and 13 AE 5% of the daily doses of Se 0 or Se(IV), respectively. The similar urinary excretions were 45 AE 4% and 53 AE 10% of the daily doses. The usefulness of the method based on in situ derivatisation of Se 0 in biological materials depended on its selectivity, accuracy and on possible associated matrix effects. In order to test the selectivity of the derivatisation method to Se 0 , Se species that are known to occur in biological materials, and therefore could interfere during the sulfite reaction, were taken through the derivatisation procedure and the reaction product analysed by anion-exchange HPLC-ICP-MS. The results in Fig. 3 demonstrated that the method was selective to Se 0 , with the exception of GSSeSG for which a small HPLC peak co-eluted with the reaction product between Se 0 NPs and sulfite,
i.e. SeSO 3 2À (lower trace). This could be caused by instability of the selenotrisulfide, which was observed to degrade at neutral or alkaline pH followed by formation of elemental Se. 27 The method was applied to the analysis of Se 0 in the biological samples and an example chromatogram is shown in ESI, † Fig. S0 . The influence of the reaction time between sulfite and Se 0 on the yield of SeSO 3 2À showed that reaction times longer than 20 minutes gave no further yield of this Se species, which was stable only for a few hours in the pre-treated biological tissue (ESI, † Fig. S1 ). The samples therefore had to be analyzed within a short time interval from the sample pre-treatment. Absolute recoveries of Se following spiking with Se 0 NPs to liver, kidneys or feces were 64-72%, and possible matrix effects on the calibration curves based on spiking with Se(VI) were undetectable as shown in ESI, † Fig. S2 .
The quantitative results for the content of Se 0 in liver, kidneys and feces are given in Fig. 4 as a fraction of total Se in each biological sample. The results demonstrated that Se 0 was indeed detected in the biological materials from animals following administration of Se 0 NPs or Se(IV) at both dose levels.
The intake of Se from the feed was 0.03 mg kg À1 bw per day, which yielded detectable Se 0 at around 5-10% of the total Se concentration in the control samples. For the rats, which were dosed 0.05 mg kg À1 bw per day, the liver and kidney samples also showed a content of Se 0 , which did not differ from the corresponding controls and did not depend on the dosage form. This suggested that the metabolic potential of Se in these organs was sufficient to convert the administered Se via natural pathways. In contrast, in the samples from rats, which were administered the ten times higher dose, i.e. 0.5 mg kg À1 bw per day, the The bioavailability and incorporation of Se into Se-proteins was monitored by SelP in plasma. Because synthesis of selenoproteins occurs as part of the suggested metabolic pathway of Se in animals and humans, the up-regulation is considered to express that both forms of administered Se were available to the pathway. NPs. 9, 12 The present findings in rats and the previously published results for mice indicate that the investigated Se-proteins were up-regulated dependent on the supplemented dose of Se, but largely independent of its chemical form.
Excretion of Se in urine
The excretion of Se (Fig. 2) and Se species metabolites was studied in urine by HPLC-ICP-MS. Despite the fact that the level of the glutathione may have been influenced by the animals' fasting at the day of collection of urine, and knowing that this reductant influences the metabolism of Se in rats, still the state of fasting is relevant both to animals and to humans e.g. while sleeping, or after the postprandial period. Representative chromatograms (ESI, † Fig. S4) show that the selenosugar, Se-methylseleno-N-acetyl-galactosamine (SeGalNAc) and trimethylselenonium-ion (TMSe + ) were detected and the semi-quantitative results are presented in Fig. 6 . It appears that for animals treated with Se 0 NPs, the concentrations of SeGalNAc are higher in the low dose animals compared to high dose animals, while the opposite pattern was observed in the animals dosed with Se(IV). However, the variation between animals is very large. The results in Fig. 6 are given as urine concentrations, and calculation of total excreted Se did not change this pattern. No TMSe + was detected in controls and low dose animals, while large amounts were observed in both high dose groups. When calculating the percentage of Se excreted as SeGalNAc and TMSe + , respectively (ESI, † Table S2 ), it appeared that in low dose animals that received both Se forms and in controls, about 70% of the Se content was excreted as SeGalNAc, while the average excretion of this Se species in high dose animals was around 20%. At the same time the TMSe + excretion increased to about 50% in both high dose groups. Thus, the average excretion patterns of SeGalNAc and TMSe + were identical after Se 0 NP or Se(IV) administration. SeGalNAc is the major metabolite in urine, 31, 32 while the presence of TMSe + is dose dependent in rats. 33 The finding that the relative TMSe + excretion increases with increasing doses of selenite in rats is thus in accordance with previous results for young rats, 33 (Fig. 2) and the similar fraction of Se 0 herein (Fig. 4) suggest that the two chemical forms were metabolized following similar pathways. Such pathways may include that Se(IV) was reduced to Se 0 , or that Se 0 NPs became dissolved and oxidized to inorganic oxoanions of Se, as both reactions were possible in a microbial environment. 3, 34 Such conversions were demonstrated using the intestinal contents from rats as medium and it was shown that Se(IV) was reduced to red elemental Se 0 by the gut microflora. 30 In a study with broiler chickens, the animals were dosed with NPs at approximately the same size as used in the present study. 35 The results showed that the nanoparticles were more effectively absorbed by the chickens in comparison with Se administered as Se(IV). The authors suggested that the Se 0 NPs were absorbed directly from the intestine, but did not present any direct evidence to support this.
Alternatively, the dosed BSA-stabilized Se 0 NPs may become dissolved in oxidized segments of the gastrointestinal tract and possibly form Se(IV) via microbial or chemical activity. 35 In this case, Se(IV) would be absorbed passively in a similar fashion for both dosage forms, and such a route would support our findings. Furthermore, the slightly higher content of Se and higher proportion of Se 0 in feces from animals given the Se 0 NPs in this study (Fig. 2 ) lends credit to this fate of Se 0 NPs in rats.
Conclusions
In conclusion, our studies have shown that Se from Se 0 NPs was absorbed and distributed to organs and excreted to the same extent as that observed for Se administered as Se ( 
